Section 4 of 6
Clinical evidence
157 evidence topics · 29 sources
Study summaries
HARMONi
Objective
Comparative efficacy and safety objective
Location and study date
Study design
Eligibility criteria
HARMONi: central nervous system eligibility
ECOG performance status eligibility
Treatment
Induction and maintenance regimens
| Treatment phase | Quoted regimen |
|---|---|
| Initial treatment | “Ivonescimab 20 mg/kg Q3W”“+Pemetrexed 500 mg/m² Q3W”“+Carboplatin AUC 5 Q3W”“4 cycles (3 weeks/cycle)” |
| Maintenance | “Ivonescimab 20 mg/kg Q3W”“+Pemetrexed 500 mg/m² Q3W” |
Study outcomes
Rationale for using progression-free survival as a primary endpoint
Regulatory rationale for progression-free survival
Statistical analysis description
Number of participants (Planned and analyzed)
HARMONi: randomized population
HARMONi: primary progression-free survival analysis population
Primary overall survival significance boundary
Description of analysis sets
HARMONi: inclusion of HARMONi-A patients in the planned analysis
Minimum exposure for the safety analysis
Results
Participant disposition
Randomized participants per group
Baseline characteristics
HARMONi: geographic representation
Efficacy results
HARMONi: primary progression-free survival
HARMONi: progression-free survival hazard ratio
HARMONi: overall response rate
HARMONi: primary overall survival analysis, median survival
| Ivonescimab plus chemotherapy | Placebo plus chemotherapy |
|---|---|
| “16.8 months” | “14.0 months” |
HARMONi: primary overall survival analysis, statistical result
HARMONi: updated overall survival analysis
HARMONi: intracranial progression-free survival, baseline brain metastases
Health-related quality of life and patient-reported outcomes
Exploratory EORTC QLQ-C30 assessment
“An exploratory endpoint was health-related quality-of-life (HRQOL) assessment using the European Organisation for Cancer Research and Treatment—Core 30 Questionnaire (EORTC QLQ-C30)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Overall, the addition of ivonescimab to chemotherapy had no detrimental impact on patient HRQOL; no clinically meaningful differences (≥10 points) between treatment groups were observed for EORTC QLQ-C30 symptoms” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Safety results
Summary
The sponsor table retains randomized arm sizes of 219. The primary publication reports safety denominators of 218 treated participants per arm.
Treated participants per arm in the primary safety analysis
Study limitations
Summary
The primary PFS analysis included 345 participants, not all 438 randomized participants. The primary OS comparison did not meet its significance boundary. The later HR of 0.76 is a follow-up result and does not replace the primary OS test. Intracranial findings were exploratory and outside the multiplicity-controlled hierarchy. Because the analysis included third-generation TKI-treated participants from HARMONi-A, the two trials should not be pooled as independent populations. The comparator was chemotherapy alone, not another active post-TKI combination.
HARMONi-A
Objective
Comparison against chemotherapy alone after EGFR-TKI progression
“To compare the efficacy of ivonescimab plus chemotherapy with chemotherapy alone for patients with relapsed advanced or metastatic non–small cell lung cancer with the epidermal growth factor receptor (EGFR) variant.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For patients with non–small cell lung cancer whose disease progressed while receiving EGFR tyrosine kinase inhibitor (EGFR-TKI) therapy, particularly third-generation TKIs, optimal treatment options remain limited.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Location and study date
HARMONi-A: setting
| Evidence element | Direct quotation |
|---|---|
| Setting | “55 sites in China”View highlighted excerpt for this quote |
Study design
Eligibility criteria
ECOG performance status eligibility
Treatment
Study outcomes
Rationale for using IRRC-assessed progression-free survival as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
HARMONi-A: enrollment
| Evidence element | Direct quotation |
|---|---|
| Enrollment | “322”View highlighted excerpt for this quote |
Planned statistical design
| Design element | Quoted value |
|---|---|
| Planned participants | “320”View highlighted excerpt for this quote |
| Planned PFS events | “225”View highlighted excerpt for this quote |
| Power | “89%”View highlighted excerpt for this quote |
| Target hazard ratio | “0.65”View highlighted excerpt for this quote |
| Interim significance boundary | “.024”View highlighted excerpt for this quote |
Description of analysis sets
Time-to-event estimation method
Results
Participant disposition
Baseline characteristics
Median age at the final survival analysis
Efficacy results
HARMONi-A: initial progression-free survival
| Evidence element | Direct quotation |
|---|---|
| Median progression-free survival, ivonescimab plus chemotherapy, months | “7.1 (95% CI, 5.9-8.7)”View highlighted excerpt for this quote |
| Median progression-free survival, placebo plus chemotherapy, months | “4.8 (95% CI, 4.2-5.6)”View highlighted excerpt for this quote |
| Progression-free survival comparison | “hazard ratio [HR], 0.46 [95% CI, 0.34-0.62]; P < .001”View highlighted excerpt for this quote |
HARMONi-A: final overall survival
| Evidence element | Direct quotation |
|---|---|
| Median overall survival, ivonescimab plus chemotherapy versus placebo plus chemotherapy | “16.8 months vs 14.1 months”View highlighted excerpt for this quote |
| Overall survival comparison | “hazard ratio, 0.74; 95% CI, 0.58-0.95; P = .02”View highlighted excerpt for this quote |
HARMONi-A: objective response and prespecified subgroups
“The prespecified subgroup analysis showed progression-free survival benefit favoring patients receiving ivonescimab over placebo across almost all subgroups, including patients whose disease progressed while receiving third-generation EGFR-TKI therapy (HR, 0.48 [95% CI, 0.35-0.66]) and those with brain metastases (HR, 0.40 [95% CI, 0.22-0.73]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The objective response rate was 50.6% (95% CI, 42.6%-58.6%) with ivonescimab and 35.4% (95% CI, 28.0%-43.3%) with placebo (difference, 15.6% [95% CI, 5.3%-26.0%]; P = .006).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
HARMONi-A: final safety analysis
| Evidence element | Direct quotation |
|---|---|
| Safety outcome | “Grade 3 or higher treatment-emergent adverse events”View highlighted excerpt for this quote |
| Ivonescimab plus chemotherapy | “67.1%”View highlighted excerpt for this quote |
| Placebo plus chemotherapy | “54.7%”View highlighted excerpt for this quote |
HARMONi-A: adverse events of special interest at the primary analysis
“Grade 3 or higher treatment-emergent adverse events occurred in 99 patients (61.5%) in the ivonescimab group vs 79 patients (49.1%) in the placebo group, the most common of which were chemotherapy-related.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Grade 3 or higher immune-related adverse events occurred in 10 patients (6.2%) in the ivonescimab group vs 4 (2.5%) in the placebo group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Grade 3 or higher vascular endothelial growth factor–related adverse events occurred in 5 patients (3.1%) in the ivonescimab group vs 4 (2.5%) in the placebo group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Study limitations
Summary
All 322 participants were enrolled at sites in China, which limits direct geographic generalization. The initial publication reported PFS; the subsequent final OS publication should be considered separately rather than treating early survival immaturity as a continuing limitation. The final OS comparison favored ivonescimab, but grade 3 or higher TEAEs were reported in 67.1% versus 54.7%. HARMONi incorporates an overlapping third-generation TKI-treated population, so its findings are not wholly independent replication.
HARMONi-A correspondence: methodology and interpretation concerns
HARMONi-A correspondence: authors’ reply
AK112-201
Objective
Location and study date
Study design
Phase II study: design
| Evidence element | Direct quotation |
|---|---|
| Design | “open-label, multicenter, phase II”View highlighted excerpt for this quote |
Eligibility criteria
Phase II study: EGFR-mutated cohort
| Evidence element | Direct quotation |
|---|---|
| Population | “The participants in cohort 2 had advanced NSCLC with EGFR-sensitive mutations”View highlighted excerpt for this quote |
Treatment
Study outcomes
Rationale for using objective response rate as a primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Participants in the EGFR-mutated cohort
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Efficacy results
Phase II study: EGFR-mutated cohort efficacy
| Evidence element | Direct quotation |
|---|---|
| Objective response rate, cohort 2 | “68.4% (13/19) [95% CI, 43.4-87.4]”View highlighted excerpt for this quote |
| Median progression-free survival, cohort 2, months | “8.5 [95% CI, 5.5-NE]”View highlighted excerpt for this quote |
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Study-wide severe white blood cell count decrease
Study limitations
Summary
The EGFR-mutated cohort contained 19 participants in an open-label study without a concurrent randomized comparator. Its ORR confidence interval was 43.4% to 87.4%, and the PFS upper confidence limit was not estimable. These results do not establish a comparative survival benefit. The study-wide safety percentage is not an EGFR-cohort-specific estimate.
MARIPOSA-2
Objective
Location and study date
Study design
Eligibility criteria
Treatment
Randomized treatment groups
| Group | Quoted regimen |
|---|---|
| Combination with lazertinib | “amivantamab-lazertinib-chemotherapy”View highlighted excerpt for this quote |
| Control | “chemotherapy”View highlighted excerpt for this quote |
| Combination without lazertinib | “amivantamab-chemotherapy”View highlighted excerpt for this quote |
Study outcomes
Rationale for using progression-free survival as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Efficacy results
Median progression-free survival
| Amivantamab plus chemotherapy, months | Amivantamab plus lazertinib and chemotherapy, months | Chemotherapy, months |
|---|---|---|
| “6.3”View highlighted excerpt for this quote | “8.3”View highlighted excerpt for this quote | “4.2”View highlighted excerpt for this quote |
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Study limitations
Summary
This trial compares amivantamab-based combinations with chemotherapy, not with ivonescimab. Its PFS results therefore cannot establish the relative efficacy of amivantamab and ivonescimab. Toxicities span hematologic, EGFR-related, and MET-related categories; a PFS comparison alone does not summarize the full benefit-risk balance.
KEYNOTE-789
Objective
Location and study date
Analysis data cutoffs
| Analysis | Quoted date |
|---|---|
| Final PFS testing | “December 3, 2021”View highlighted excerpt for this quote |
| Final OS analysis | “January 17, 2023”View highlighted excerpt for this quote |
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using progression-free survival as a primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Randomized participants by group
| Pembrolizumab plus chemotherapy | Placebo plus chemotherapy |
|---|---|
| “245”View highlighted excerpt for this quote | “247”View highlighted excerpt for this quote |
Description of analysis sets
Prespecified efficacy threshold and PFS test
| Statistical quantity | Quoted value |
|---|---|
| One-sided efficacy boundary for PFS and OS | “.0117”View highlighted excerpt for this quote |
| Observed one-sided PFS P value | “.0122”View highlighted excerpt for this quote |
Results
Participant disposition
Baseline characteristics
No evidence found.
Efficacy results
Median survival outcomes
| Outcome | Pembrolizumab plus chemotherapy, months | Placebo plus chemotherapy, months |
|---|---|---|
| PFS | “5.6”View highlighted excerpt for this quote | “5.5”View highlighted excerpt for this quote |
| OS | “15.9”View highlighted excerpt for this quote | “14.7”View highlighted excerpt for this quote |
Comparator trial: primary efficacy conclusion
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Grade 3 or higher treatment-related adverse events
| Pembrolizumab plus chemotherapy | Placebo plus chemotherapy |
|---|---|
| “43.7%”View highlighted excerpt for this quote | “38.6%”View highlighted excerpt for this quote |
Study limitations
Summary
The PFS P value of 0.0122 did not meet the prespecified one-sided boundary of 0.0117. Neither primary efficacy endpoint was met. These results concern pembrolizumab plus chemotherapy, not ivonescimab, and cannot determine the effect of simultaneous PD-1 and VEGF inhibition.
CheckMate 722
Objective
Location and study date
Study design
Eligibility criteria
Treatment
Nivolumab dose with chemotherapy
Study outcomes
Rationale for using progression-free survival as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Planned and randomized participants
| Quantity | Quoted count |
|---|---|
| Original enrollment target | “500”View highlighted excerpt for this quote |
| Revised enrollment target | “270”View highlighted excerpt for this quote |
| Randomized participants | “294”View highlighted excerpt for this quote |
Description of analysis sets
Estimated statistical power with observed PFS events
Results
Participant disposition
Treated participants
| Nivolumab plus chemotherapy | Chemotherapy |
|---|---|
| “141”View highlighted excerpt for this quote | “143”View highlighted excerpt for this quote |
Baseline characteristics
Efficacy results
Median progression-free survival
| Nivolumab plus chemotherapy, months | Chemotherapy, months |
|---|---|
| “5.6”View highlighted excerpt for this quote | “5.4”View highlighted excerpt for this quote |
Health-related quality of life and patient-reported outcomes
Safety results
Grade 3 or 4 treatment-related adverse events
| Nivolumab plus chemotherapy | Chemotherapy |
|---|---|
| “44.7%”View highlighted excerpt for this quote | “29.4%”View highlighted excerpt for this quote |
Study limitations
Summary
The enrollment target was reduced from 500 to 270 participants, and the estimated power with observed PFS events was 76%. The open-label study did not meet its primary PFS endpoint. Grade 3 or 4 TRAEs were reported in 44.7% versus 29.4%. The trial evaluates nivolumab, not ivonescimab.
COMPEL
Objective
Location and study date
Geographic scope
Study design
Allocation and masking
Eligibility criteria
Progression pattern required for enrollment
Treatment
Experimental and control oral treatments
Study outcomes
Rationale for using investigator-assessed progression-free survival as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Randomized participants per arm
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Efficacy results
Overall survival hazard ratio: 95% confidence interval
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Study limitations
Summary
There were 49 participants per arm, and eligibility required non-CNS progression. The OS hazard-ratio confidence interval included 1, so the numerical median OS difference does not establish an OS benefit. This study does not directly compare osimertinib continuation with ivonescimab.
TROPION-Lung05
Objective
Molecularly selected study population
Location and study date
Snapshot data cutoff
“The data cutoff date for the primary analysis (ie, when all patients had ≥9 months of follow-up after treatment initiation or had discontinued from the study, whichever occurred first) was December 14, 2022.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Study design
Eligibility criteria
Treatment
Datopotamab deruxtecan dose
Study outcomes
Rationale for using objective response rate as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Genomic alteration groups
| EGFR-mutated | ALK-rearranged |
|---|---|
| “56.9%”View highlighted excerpt for this quote | “24.8%”View highlighted excerpt for this quote |
Efficacy results
Objective response rate
| Overall study population | EGFR-mutated subgroup |
|---|---|
| “35.8%”View highlighted excerpt for this quote | “43.6%”View highlighted excerpt for this quote |
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Study-wide safety outcomes
| Safety outcome | Quoted percentage |
|---|---|
| Grade 3 or higher treatment-related adverse events | “28.5%”View highlighted excerpt for this quote |
| Adjudicated treatment-related interstitial lung disease or pneumonitis | “3.6%”View highlighted excerpt for this quote |
| Grade 5 interstitial lung disease or pneumonitis | “0.7%”View highlighted excerpt for this quote |
Study limitations
Summary
The 137-participant population included multiple genomic subgroups; 56.9% had EGFR mutations. The overall ORR and safety percentages should not be presented as EGFR-specific estimates. The EGFR-subgroup ORR of 43.6% is not a randomized comparison with ivonescimab.
Case report: malignant pleural effusion and acquired complex resistance
Objective
Clinical question: acquired resistance
Location and study date
Study design
Eligibility criteria
Not applicable.
Treatment
Study outcomes
Rationale for using radiographic disease control as the reported outcome
Not applicable.
Statistical analysis description
Number of participants (Planned and analyzed)
Not applicable.
Description of analysis sets
Not applicable.
Results
Participant disposition
Baseline characteristics
Efficacy results
Case report: malignant pleural effusion and acquired complex resistance
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Study limitations
Summary
This single-participant case cannot estimate a comparative treatment effect or establish that the reported resistance pattern predicts benefit. Disease control during monotherapy and subsequent combination treatment should not be conflated. The qualitative safety description does not provide an adverse-event rate.
Case report: lung adenosquamous carcinoma after multiline therapy
Objective
Location and study date
Initial imaging date
Study design
Eligibility criteria
Not applicable.
Treatment
Ivonescimab regimen
Study outcomes
Rationale for using radiographic partial response as the reported outcome
Not applicable.
Statistical analysis description
Number of participants (Planned and analyzed)
Not applicable.
Description of analysis sets
Not applicable.
Results
Participant disposition
Baseline characteristics
Baseline age, EGFR alterations, and PD-L1 expression
Efficacy results
Radiographic response
Case report: lung adenosquamous carcinoma after multiline therapy
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Study limitations
Summary
The report describes one participant with adenosquamous histology and multiple previous therapies. A response sustained over six cycles cannot establish an OS benefit, comparative efficacy, or the frequency of uncommon toxicity. The findings should not be generalized to all EGFR-mutated NSCLC.
HARMONi-5
Objective
Location and study date
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using objective response rate as a primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Enrolled and treated participants
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Participants with PD-L1 tumor proportion score of at least 1%
Efficacy results
Overall objective response rate
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Study-wide treatment-related adverse events
| Outcome | Quoted percentage |
|---|---|
| Grade 3 or higher TRAEs | “22.2%”View highlighted excerpt for this quote |
| TRAEs leading to death, reported in squamous NSCLC | “2.8%”View highlighted excerpt for this quote |
Study limitations
Summary
This phase 1b evidence concerns monotherapy, not the chemotherapy combination evaluated in the pivotal trials. Grade 3 or higher TRAEs occurred in 22.2%, and TRAEs leading to death were reported in 2.8%. The monotherapy response estimate should not be substituted for post-TKI combination-treatment efficacy.
AK112-101
Objective
Location and study date
Enrollment dates reported in the publication
| Date element | Quoted date |
|---|---|
| Enrollment start | “October 2, 2019”View highlighted excerpt for this quote |
| Enrollment end in the abstract | “January 14, 2021”View highlighted excerpt for this quote |
| Enrollment end in the results section | “June 14, 2021”View highlighted excerpt for this quote |
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using treatment-emergent adverse events as the primary endpoint
Not applicable.
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Results
Participant disposition
Participants with at least one postbaseline tumor assessment
Baseline characteristics
Efficacy results
Antitumor activity among response-evaluable participants
| Confirmed objective response rate | Disease control rate |
|---|---|
| “25.5%”View highlighted excerpt for this quote | “63.8%”View highlighted excerpt for this quote |
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Grade 3 or higher treatment-related adverse events
Study limitations
Summary
The study enrolled 51 participants with advanced solid tumors, with 47 contributing a postbaseline response assessment. Descriptive dose-escalation findings do not establish efficacy specifically in EGFR-mutated NSCLC. The publication gives different enrollment end dates in its abstract and results section; neither date has been silently substituted for the other. The maximum tolerated dose is specific to this study and schedule.
AK112-102
Objective
Clinical pharmacology objectives
Location and study date
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using treatment-emergent adverse events as the primary endpoint
Not applicable.
Statistical analysis description
Number of participants (Planned and analyzed)
Planned and treated participants
| Quantity | Quoted count |
|---|---|
| Planned enrollment | “Fifty-four”View highlighted excerpt for this quote |
| Treated participants | “59”View highlighted excerpt for this quote |
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Representation of non-small-cell lung cancer
| Baseline characteristic | Quoted count and percentage |
|---|---|
| Participants with non-small-cell lung cancer, n (%) | “1 (1.7)”View highlighted excerpt for this quote |
Efficacy results
No evidence found.
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Treatment-related adverse events
| Outcome | Quoted percentage |
|---|---|
| Grade 3 or higher TRAEs | “23.7%”View highlighted excerpt for this quote |
| Serious TRAEs | “11.9%”View highlighted excerpt for this quote |
Study limitations
Summary
Only 1 of 59 participants, 1.7%, had NSCLC. These descriptive safety and pharmacology findings cannot establish efficacy for EGFR-mutated NSCLC. Unlike the Australian phase 1a study, this study did not reach a maximum tolerated dose; the results should not be merged into a single universal maximum-dose conclusion.